Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Find generic entry opportunities
|Title:||Method of identifying freeze-dried dosage forms|
|Abstract:||The invention permits the application of an identifying mark onto a freeze-dried tablet without the need for application of pressure or for printing directly on the tablet. The invention comprises the preparation of a freeze-dried unit that is embossed with an identifying mark such as a manufacturer's logo, medicinal component strength, or other information relating to the unit. The desired identifying mark is first embossed onto the base of a container such as a blister pocket. Liquid suspension is then filled into the container and freeze-dried therein. The resulting freeze-dried unit in the container is thereby embossed with substantial copy of the identifying mark that was embossed on the base of the container. The embossed identifying mark on the base of the container remains thereon as well, providing at reduced manufacturing cost the added ability to learn the identifying mark on the enclosed freeze-dried unit without opening the blister pack.|
|Inventor(s):||Thompson; Andrew R. (Swindon, GB3), Yarwood; Richard J. (Buckland, GB3), Kearney; Patrick (Swindon, GB3)|
|Assignee:||R. P. Scherer Corporation (Troy, MI)|
Patent Claim Types:|
see list of patent claims
|Use; Dosage form; Process;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.